1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
(
- Contribution to journal › Article
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
- 2023
-
Mark
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
(
- Contribution to journal › Article
-
Mark
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
(
- Contribution to journal › Article
- 2021
-
Mark
CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial
(
- Contribution to journal › Article
-
Mark
Adjuvant imatinib for GIST : duration likely matters
(
- Contribution to journal › Debate/Note/Editorial
- 2019
-
Mark
Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden : A SCAN-LEAF study analysis from the I-O Optimise initiative
(
- Contribution to journal › Published meeting abstract
-
Mark
Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden : A SCAN-LEAF study analysis from the I-O Optimise initiative
(
- Contribution to journal › Published meeting abstract
-
Mark
The role of plasma microseminoprotein-beta in prostate cancer : An observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition
(
- Contribution to journal › Article
-
Mark
Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3)
(
- Contribution to journal › Article